Advanced Drug Delivery Systems in the Management of Cancer discusses recent developments in nanomedicine and nano-based drug delivery systems used in the treatment of cancers affecting the blood, lungs, brain, and kidneys. The research presented in this book includes international collaborations in the area of novel drug delivery for the treatment of cancer. Cancer therapy remains one of the greatest challenges in modern medicine, as successful treatment requires the elimination of malignant cells that are closely related to normal cells within the body. Advanced drug delivery systems are carriers for a wide range of pharmacotherapies used in many applications, including cancer treatment. The use of such carrier systems in cancer treatment is growing rapidly as they help overcome the limitations associated with conventional drug delivery systems. Some of the conventional limitations that these advanced drug delivery systems help overcome include nonspecific targeting, systemic toxicity, poor oral bioavailability, reduced efficacy, and low therapeutic index. This book begins with a brief introduction to cancer biology. This is followed by an overview of the current landscape in pharmacotherapy for the cancer management. The need for advanced drug delivery systems in oncology and cancer treatment is established, and the systems that can be used for several specific cancers are discussed. Several chapters of the book are devoted to discussing the latest technologies and advances in nanotechnology. These include practical solutions on how to design a more effective nanocarrier for the drugs used in cancer therapeutics. Each chapter is written with the goal of informing readers about the latest advancements in drug delivery system technologies while reinforcing understanding through various detailed tables, figures, and illustrations. Advanced Drug Delivery Systems in the Management of Cancer is a valuable resource for anyone working in the fields of cancer biology and drug delivery, whether in academia, research, or industry. The book will be especially useful for researchers in drug formulation and drug delivery as well as for biological and translational researchers working in the field of cancer. Presents an overview of the recent perspectives and challenges within the management and diagnosis of cancer Provides insights into how advanced drug delivery systems can effectively be used in the management of a wide range of cancers Includes up-to-date information on diagnostic methods and treatment strategies using controlled drug delivery systems

In recent years, nanoparticles—bionanomaterials with specific physicochemical properties—have gained a great deal of scientific interest owing to their unique structure. Nanoparticle-based drugs are now widely regarded as a safer, more precise, and more effective mode of cancer therapy, considering their ability to enhance drug bioavailability, improve site-specific drug delivery, and protect nontarget tissues from toxic therapeutic drugs. This book compiles and details cutting-edge research in nanomedicine from an interdisciplinary team of international cancer researchers who are currently revolutionizing drug delivery techniques through the development of nanomedicines and nanotheranostics. Edited by Hala Gali-Muhtasib and Racha Chouaib, two prominent cancer researchers, this book will appeal to anyone involved in nanotechnology, cancer therapy, or drug delivery research.

Leading experts survey the currently available technologies designed to improve the delivery of today's cancer chemotherapeutic agents. The authors review both the theoretical and practical considerations governing conventional and nonconventional methods of drug administration, and identify promising opportunities for product development. In their outline and discussion of the use of novel formulation technologies-including synthetic polymers and biomaterials for prolonged or sustained drug release to achieve potentially greater therapeutic effect-they profile those technologies that have resulted in a number of approved and late-stage clinical products.

Presents nanobiotechnology in drug delivery and disease management Featuring contributions from noted experts in the field, this book highlights recent advances in the nano-based drug delivery systems. It also covers the diagnosis and role of various nanomaterials in the management of infectious diseases and non-infectious disorders, such as cancers and other malignancies and their role in future medicine. Nanobiotechnology in Diagnosis, Drug Delivery and Treatment starts by introducing how nanotechnology has revolutionized drug delivery, diagnosis, and treatments of diseases. It then focuses on the role of various nanocomposites in diagnosis, drug delivery, and treatment of diseases like cancer, Alzheimer's disease, diabetes, and many others. Next, it discusses the application of a variety of nanomaterials in the diagnosis and management of gastrointestinal tract disorders. The book explains the concept of nanotheranostics in detail and its role in effective monitoring of drug response, targeted drug delivery, enhanced drug accumulation in the target tissues, sustained as well as triggered release of drugs, and reduction in adverse effects. Other chapters cover aptamer-incorporated nanoparticle systems; magnetic nanoparticles; theranostics and vaccines; toxicological concerns of nanomaterials used in nanomedicine; and more. Provides a concise overview of state-of-the-art nanomaterials and their application like drug delivery in infectious diseases and non-infectious disorders Highlights recent advances in the nano-based drug delivery systems and role of various nanomaterials Introduces nano-based sensors which detect various pathogens Covers the use of nanodevices in diagnostics and theranostics Nanobiotechnology in Diagnosis, Drug Delivery and Treatment is an ideal book for researchers and scientists working in various disciplines such as microbiology, biotechnology, nanotechnology, pharmaceutical biotechnology, pharmacology, pharmaceutics, and nanomedicine.

This book takes a systematic approach to address the gaps relating to nanomedicine and bring together fragmented knowledge on the advances on nanomaterials and their biomedical applicability. In particular, it demonstrates an exclusive compilation of state of the art research with a focus on fundamental concepts, current trends, limitations, and future directions of nanomedicine.

Nanobiomaterials in Cancer Therapy

This volume presents papers on the topics covered at the National Academy of Engineering's 2018 US Frontiers of Engineering Symposium. Every year the symposium brings together 100 outstanding young leaders in engineering to share their cutting-edge research and innovations in selected areas. The 2018 symposium was held September 5-7 and hosted by MIT Lincoln Laboratory in Lexington, Massachusetts. The intent of this book is to convey the excitement of this unique meeting and to highlight innovative developments in engineering research and technical work.

Drug Repurposing in Cancer Therapy: Approaches and Applications provides comprehensive and updated information from experts in basic science research and clinical practice on how existing drugs can be repurposed for cancer treatment. The book summarizes successful stories that may assist researchers in the field to better design their studies for new repurposing projects. Sections discuss specific topics such as in silico prediction and high throughput screening of repurposed drugs, drug repurposing for overcoming chemoresistance and eradicating cancer stem cells, and clinical investigation on combination of repurposed drug and anticancer therapy. Cancer researchers, oncologists, pharmacologists and several members of biomedical field who are interested in learning more about the use of existing drugs for different purposes in cancer therapy will find this to be a valuable resource. - Presents a systematic and up-to-date collection of the research underpinning the various drug repurposing approaches for a quick, but in-depth understanding on current trends in drug repurposing research - Brings better understanding of the drug repurposing process in a holistic way, combining both basic and clinical sciences - Encompasses a collection of successful stories of drug repurposing for cancer therapy in different cancer types

This book is the third volume on this subject and focuses on the recent advances of nanopharmaceuticals in cancer, dental, dermal and drug delivery applications and presents their safety, toxicity and therapeutic efficacy. The book also includes the transport phenomenon of nanomaterials and important pathways for drug delivery applications. It goes on to explain the toxicity of nanoparticles to different physiological systems and methods used to assess this for different organ systems using examples of in vivo systems.

Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€"by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€"to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.